Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 11/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29520095 | 1.00 | FGFR3 (0.47) | FGFR3KDRSCDSTING1MAPT | |
| SCHEMBL3410381 | 0.91 | SMARCA2 (0.42) | FGFR3KDRSCDSTING1SMARCA2 | |
| SCHEMBL13209251 | 0.80 | MAPT (0.46) | SCDSTING1MAPTSMARCA2SMARCA4 | |
| SCHEMBL16977662 | 0.79 | SCD (0.42) | FGFR3KDRSCDMAPK1 | |
| SCHEMBL19370344 | 0.79 | STING1 (0.43) | FGFR3KDRSCDSTING1MAPT | |
| SCHEMBL4517082 | 0.79 | SMARCA2 (0.48) | FGFR3KDRSCDSTING1MAPT | |
| SCHEMBL15594489 | 0.79 | ALDH1A1 (0.35) | SCDMAPT | |
| SCHEMBL15594374 | 0.78 | KDM5B (0.39) | FGFR3 | |
| SCHEMBL24921987 | 0.77 | MAPT (0.50) | FGFR3KDRSCDSTING1MAPT | |
| SCHEMBL15576056 | 0.77 | CHRNB2 (0.39) | FGFR3SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872976-B | Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of pharmaceutical composition | 中国药科大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-115872976-A | Quinoline derivative, pharmaceutical composition containing quinoline derivative and application of quinoline derivative | 中国药科大学 | 2023-03-31 | — | — | CN | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| EP-3759106-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Karus Therapeutics Ltd (GB) | 2021-01-06 | — | — | EP | disclosed |
| CN-112004814-A | Oxadiazolyl thiophene derivatives useful as inhibitors of histone deacetylase | 卡鲁斯治疗有限公司 | 2020-11-27 | — | — | CN | disclosed |
| CN-106279176-B | Deuterated 3- [ (6-quinolyl) difluoromethyl ] -6- [ (1-methyl) -4-pyrazolyl ] [1,2,4] triazolo [4,3-b ] pyridazine and application thereof | 中国科学院上海药物研究所 | 2020-09-08 | — | — | CN | disclosed |
| US-10464939-B2 | Deuterated triazolopyridazine as a kinase modulator | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-05 | — | — | US | disclosed |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| WO-2008155378-A1 | POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155378-A1 | POLYMORPHIC AND HYDRATE FORMS, SALTS AND PROCESS FOR PREPARING 6-{DIFLUORO[6-(1-METHYL-1H-PYRAZOL-4-YL)[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-3-YL]METHYL}QUINOLINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | WO | disclosed |
| EP-1966214-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | MET, ABL1, KRAS | FGFR3 436/4885KDR 339/4885SCD 3822/4885 |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | FGFR3 223/4885KDR 121/4885SCD 4756/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | FGFR3 450/4885KDR 4056/4885SCD 2895/4885 |
| US-10464939-B2 | Deuterated triazolopyridazine as a kinase modulator | MET, DMPK, ABL1 | FGFR3 382/4885KDR 632/4885SCD 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.